Ambry Genetics Reaffirms Status as Worldwide Leader in Hereditary Cancer Testing With New Renal, Pancreatic and PGL-PCC Panels

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, the worldwide leader in hereditary cancer testing, announced today that it has officially launched its next-generation sequencing (NGS) renal, pancreatic and paraganglioma-pheochromocytoma (PGL/PCC) hereditary cancer panels.

Help employers find you! Check out all the jobs and post your resume.

Back to news